Interim report Q3 2025 out now

23 October 2025

Continued profitability and clinical evidence supporting future growth

Third quarter 2025 (July – September)

  • Total revenue amounted to SEK 48.4 (73.9) million, a decrease of SEK 25.5 million corresponding to 34.5%.
  • Net sales amounted to SEK 45.5 (67.3) million, a decrease of SEK 21.9 million corresponding to 32.5%. Adjusted for currency effects of SEK -3.4 million, net sales decreased by 27.4%.
  • Operating loss amounted to SEK 6.4 (1.9) million.
  • EBITDA amounted to SEK 5.3 (9.9) million.
  • Net loss for the period amounted to SEK 7.5 (4.7) million.
  • Loss per share, before and after dilution, amounted to SEK 0.21 (0.13).
  • Cash flow from operating activities amounted to SEK -2.8 (8.3) million corresponding to SEK -0.08 (0.24) per share.

The period January – September 2025

  • Total revenue amounted to SEK 163.2 (193.6) million, a decrease of SEK 30.4 million corresponding to 15.7%.
  • Net sales amounted to SEK 152.8 (178.6) million, a decrease of SEK 25.9 million corresponding to 14.5%. Adjusted for currency effects of SEK -5.4 million, net sales decreased by 11.5%.
  • Operating loss amounted to SEK 16.3 (25.7) million.
  • EBITDA amounted to SEK 19.1 (9.6) million.
  • Net loss for the period amounted to SEK 20.4 (28.9) million.
  • Loss per share, before and after dilution, amounted to SEK 0.59 (0.82).
  • Cash flow from operating activities amounted to SEK -13.2 (6.1) million corresponding to SEK -0.38 (0.17) per share.

Christine Lind, CEO of Bactiguard comments:

“The profitability trend continued during the third quarter with an EBITDA of SEK 5.3 million (Q3 2024: SEK 9.9 million). Revenues amounted to SEK 48.4 (Q3 2024: SEK 73.9 million) with license revenues of SEK 29.9 million (Q3 2024: 47.5 million). The comparison is impacted by a weaker USD and high base from last year. The Wound Management portfolio revenues totalled SEK 15.6 million (Q3 2024: SEK 17.9 million) with continued growth in Hydrocyn aqua, but a decline in sutures.”

 

The full report for the third quarter 2025 is available at https://ir.bactiguard.com/

Back to all updates

From the same category